CD274 and non-small cell lung carcinoma: In October 2022, based on the results of the phase 3 trial Impower-010, the Food and Drug Administration (FDA) approved adjuvant anti-PD-L1 atezolizumab for patients with stage II–IIIA (according to the AJCC VII edition) NSCLC and a PD-L1 expression >1%, after surgery and platinum-based chemotherapy [70].